Free Trial

IDEXX Laboratories (IDXX) Stock Forecast & Price Target

IDEXX Laboratories logo
$631.19 -2.65 (-0.42%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$629.46 -1.73 (-0.27%)
As of 05:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
4
Buy
8

Based on 12 Wall Street analysts who have issued ratings for IDEXX Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 4 have given a hold rating, 7 have given a buy rating, and 1 has given a strong buy rating for IDXX.

Consensus Price Target

$656.50
4.01% Upside
According to the 12 analysts' twelve-month price targets for IDEXX Laboratories, the average price target is $656.50. The highest price target for IDXX is $785.00, while the lowest price target for IDXX is $520.00. The average price target represents a forecasted upside of 4.01% from the current price of $631.19.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for IDXX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IDEXX Laboratories and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IDXX Analyst Ratings Over Time

TypeCurrent Forecast
10/6/24 to 10/6/25
1 Month Ago
9/6/24 to 9/6/25
3 Months Ago
7/8/24 to 7/8/25
1 Year Ago
10/7/23 to 10/6/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
Hold
4 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$656.50$649.44$558.11$582.25
Forecasted Upside4.01% Upside1.00% Upside3.58% Upside21.89% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

IDXX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IDXX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

IDEXX Laboratories Stock vs. The Competition

TypeIDEXX LaboratoriesMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.33
2.51
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside4.01% Upside1,395.17% Upside10.49% Upside
News Sentiment Rating
Positive News

See Recent IDXX News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/1/2025UBS Group
4 of 5 stars
Andrea Alfonso
Andrea Alfonso
Not Rated
Initiated CoverageNeutral$720.00+12.70%
9/27/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingBuy (B-)
8/15/2025Morgan Stanley
3 of 5 stars
Erin Wright
Erin Wright
5 of 5 stars
Boost TargetOverweight$722.00 ➝ $765.00+16.98%
8/11/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$510.00 ➝ $700.00+6.37%
8/5/2025BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$545.00 ➝ $785.00+17.88%
8/4/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Set Target$640.00-0.30%
8/4/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$550.00 ➝ $675.00-1.14%
7/17/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$580.00 ➝ $600.00+15.47%
7/1/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageBuy$625.00+16.53%
2/4/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$481.00 ➝ $520.00+10.86%
2/4/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$475.00 ➝ $535.00+14.06%
12/2/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
4/9/2024William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform
1/17/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$500.00 ➝ $650.00+25.68%
12/7/2023BNP Paribas
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageOutperform$602.00+15.42%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 05:41 AM ET.


Should I Buy IDEXX Laboratories Stock? IDXX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, October 5, 2025. Please send any questions or comments about these IDEXX Laboratories pros and cons to contact@marketbeat.com.

IDEXX Laboratories
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in IDEXX Laboratories, Inc.:

  • Recent analyst upgrades have increased target prices significantly, with JPMorgan Chase raising their target to $675.00, indicating strong market confidence in the company's growth potential.
  • The current stock price is around $620, which is near its 12-month high of $688.12, suggesting strong performance and potential for further appreciation.
  • IDEXX Laboratories, Inc. has a solid market capitalization of approximately $49.61 billion, reflecting its strong position in the animal health sector.
  • Insider activity shows confidence, with executives recently selling shares at high prices, indicating they believe the stock is performing well.
  • The company has a high percentage of institutional ownership at 87.84%, which often indicates strong investor confidence and stability.

IDEXX Laboratories
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in IDEXX Laboratories, Inc. for these reasons:

  • The stock has experienced a recent decline of about 2.9%, which may raise concerns about short-term volatility.
  • Insider sales have totaled over 54,000 shares in the last 90 days, which could signal a lack of confidence in the stock's near-term performance.
  • The company's P/E ratio is relatively high at 51.63, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Recent downgrades from some analysts, such as Wall Street Zen lowering their rating from "strong-buy" to "buy," may indicate a shift in market sentiment.
  • The stock's beta of 1.58 suggests higher volatility compared to the market, which could be a risk for more conservative investors.

IDXX Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for IDEXX Laboratories is $656.50, with a high forecast of $785.00 and a low forecast of $520.00.

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 4 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IDXX shares.

According to analysts, IDEXX Laboratories's stock has a predicted upside of 4.01% based on their 12-month stock forecasts.

IDEXX Laboratories has been rated by research analysts at BTIG Research, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Piper Sandler, Stifel Nicolaus, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like IDEXX Laboratories more than other "medical" companies. The consensus rating for IDEXX Laboratories is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how IDXX compares to other companies.


This page (NASDAQ:IDXX) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners